7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec.
Valeo Pharma today announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson’s disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l’assurance maladie du Québec, effective 1 February 2023.